ProQR Therapeutics NV reports results for the quarter ended in March - Earnings Summary

ProQR Therapeutics NV

14/05/2024 14:31

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 9 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -11 cents.  The mean expectation of six analysts
for the quarter was for a loss of 11 cents per share. Wall
Street expected results to range from -16 cents to -7 cents per
share.
    * Revenue rose 538.5% to €4.45 million from a year ago;
analysts
expected €3.14 million. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 9 cents​.
    * The company reported a quarterly loss of €7.66 million.
    * ProQR Therapeutics NV shares had fallen by 13.5% this
quarter and held steady so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 26.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ProQR
Therapeutics NV is $5.00 
This summary was machine generated from LSEG data May 14 at
01:31 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.11          -0.09          Beat
 Dec. 31 2023      0.01           -0.07          Missed
 Sep. 30 2023      -0.09          -0.07          Beat
 Jun. 30 2023      -0.11          -0.10          Beat